anastrozole / Generic mfg. - LARVOL DELTA

Hair loss in cancer patients receiving small molecule inhibitors: Evidence from clinical trials (AACR 2026) - "Hedgehog pathway inhibitors induced the highest overall rates, ranging from 20-30% with saridegib and glasdegib, and up to 63% with vismodegib. FGFR inhibitors (pemigatinib, infigratinib) and other kinase inhibitors (ripretinib, vemurafenib, sorafenib, AZD0424) demonstrated moderate rates (22-48%). Lower alopecia incidence was reported with aromatase inhibitors (anastrozole, lenostrozole) and the aurora B kinase inhibitor BI 811283, ranging from 9 to 21%...The higher incidences seen with Hedgehog inhibitors, compared with aromatase inhibitors, highlight how pathway-specific disruption of follicular signaling contributes to hair loss. Further research into the molecular mechanisms of these agents may help clinicians better anticipate and manage this side effect."

Clinical • Oncology • BRAF

Lifestyle Intervention Therapy Modulates Global DNA Methylation and Adipogenic Gene Expression in Severely Obese Hypogonadal Men. (PubMed, Metabolites) - "This is a secondary analysis of samples of severely obese (body mass index of ≥35 kg/m2) hypogonadal men undergoing weight loss from diet and exercise in addition to an aromatase inhibitor (anastrozole) or placebo for a total of 12 months... In summary, our findings suggest that LSI induces epigenetic modifications in leukocytes, possibly through the regulation of DNMT gene expression. Future studies are warranted to clarify the mechanistic pathways linking lifestyle-induced epigenetic alterations to metabolic health outcomes."

Journal • Endocrine Disorders • Genetic Disorders • Obesity • CEBPA • DNMT1 • DNMT3A • DNMT3B • FTO • PPARG

AZD4241, an orally bioavailable ERα PROTAC, degrades wild-type and mutant ERα and delivers anti-tumour activity in preclinical breast cancer models (AACR 2026) - "Current ER‑pathway inhibitors include aromatase inhibitors (letrozole, anastrozole, exemestane), selective estrogen receptor modulators (SERMs; tamoxifen), and selective estrogen receptor degraders (SERDs; fulvestrant, elacestrant, imlunestrant)...In vivo, AZD4241 induced dose‑dependent anti‑tumour activity and, in some cases, tumour regressions across ESR1wt and ESR1m patient‑derived xenograft (PDX) models, including a palbociclib‑resistant model...Collectively, these data confirm that AZD4241 is a potent, orally bioavailable degrader of wt and mutant ERα, driving anti-tumour efficacy in ESR1wt, ESR1m, and CDK4/6 inhibitor‑resistant PDX models. These findings support the use of AZD4241 as a novel ER-PROTAC with potential to overcome key resistance mechanisms to current standards of care and deliver clinical benefit for patients with ER‑positive breast cancer."

Preclinical • Breast Cancer • Estrogen Receptor Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • CRBN • TFF1

Causal machine learning personalizes endocrine therapy selection for ductal carcinoma in situ (AACR 2026) - "Our causal machine learning model accurately predicted who would benefit from anastrozole vs tamoxifen, outperforming treatment selection based on age alone. Once validated, this model may help clinicians optimize treatment selection for post-menopausal women with DCIS. This work was supported by NLM 5T15LM007359."

Machine learning • Breast Cancer • Oncology

Combinatorial screening reveals novel gene-drug synergies in breast cancer cells (AACR 2026) - "In MCF-7 cells, silencing R3HDM2 markedly increased sensitivity to CDK4/6 inhibitors, with fold-changes >8 for abemaciclib and >4 for palbociclib, implicating a critical role in cell cycle regulation...In T47D cells, knockdown of SLC25A12, DNAJC27, and DYNC1I2 genes sensitized cells to everolimus, docetaxel, and lapatinib (fold-change >14, >6, and >5). In MDA-MB-231 cells, knockdown of CEP192 and SLC25A12 genes significantly enhanced sensitivity to anastrozole and docetaxel (fold-change >7 and >4). Knockdown of several newly identified putative breast cancer susceptibility genes profoundly altered drug sensitivity in breast cancer cells, revealing mechanistic insights and potential drug targets for breast cancer. Knockdown of several newly identified putative breast cancer susceptibility genes profoundly altered drug sensitivity in breast cancer cells, revealing mechanistic insights and potential drug targets for breast cancer. Genes such as R3HDM2,..."

Breast Cancer • Oncology • Solid Tumor • DYNC1I2

Clinicopathologic Spectrum of Cystic Hypersecretory Breast Lesions and Ki-67 Index Analysis (USCAP 2026) - "Post-lumpectomy, 2 received radiation, and one anastrozole... Consistent with prior reports, all CHCs in our cohort arose in a background of CHH or atypical CHH. Despite having high nuclear grade, none of the CHC cases in our cohort expressed >10% Ki-67 index suggesting it might not be a useful tool to distinguish CHC from other lesions in the spectrum. This finding coupled with no follow-up events suggests that CHC without invasion usually has indolent behavior."

Clinical • Breast Cancer

DESTINY-Breast08: a phase 1b study of trastuzumab deruxtecan in combination with other anticancer therapies in patients with HER2-low metastatic breast cancer. (PubMed, Clin Cancer Res) - "Safety results were generally consistent with known individual profiles for T-DXd and combination drugs. T-DXd plus capecitabine, capivasertib, anastrozole, or fulvestrant demonstrated preliminary clinical activity in patients with HER2-low mBC."

Journal • P1 data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Interstitial Lung Disease • Oncology • Pneumonia • Pulmonary Disease • Respiratory Diseases • Solid Tumor • HER-2

J6M-MC-JSGD: A Study of LY4064809 With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) (clinicaltrialsregister.eu) - P2/3 | N=36 | Not yet recruiting | Sponsor: Eli Lilly & Co.

New P2/3 trial • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • PIK3CA

MINIMAL CHANGE DISEASE ASSOCIATED WITH RIBOCICLIB: A NOVEL RENAL COMPLICATION OF CDK4/6 INHIBITOR THERAPY (ISN-WCN 2026) - "The three FDA-approved agents-ribociclib, palbociclib, and abemaciclib-are oral therapies used long-term until disease progression...She was treated with anastrozole and palbociclib, but within two months developed AKI (Cr 1.93 mg/dL) with hypomagnesemia (0.5 mg/dL) and hypocalcemia (6.6 mg/dL), which resolved after discontinuation...Prednisone was then discontinued and cyclosporine initiated, reducing UPCR to 1.01g/g by March 2025, but creatinine rose to 3.19 mg/dL with hypertension, hyperlipidemia, and headaches. Cyclosporine was stopped, and the patient received rituximab, after which UPCR improved to 0.6 g/g by September 2025. Her cancer has remained in remission since the time of ribociclib initiation.Conclusion CDK4/6 inhibitors are increasingly used in hormone receptor–positive breast cancer and can affect kidney function through both functional and structural mechanisms. This is the first case to describe minimal change disease that occurred in association with..."

Atherosclerosis • Back Pain • Breast Cancer • Diabetes • Dyslipidemia • Endocrine Disorders • Glomerulonephritis • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Hypertension • Metabolic Disorders • Musculoskeletal Pain • Solid Tumor • Type 2 Diabetes Mellitus • HER-2 • PGR

Camizestrant + CDK4/6 inhibitor (CDK4/6i) for the treatment of emergent ESR1 mutations during first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC): Phase 3, double-blind ctDNA-guided SERENA-6 trial. (ASCO 2025) - P3 | " Pts with HR+/HER2– ABC who had received ≥6 months of 1L AI (anastrozole/letrozole) + CDK4/6i (abemaciclib/palbociclib/ribociclib) were enrolled and had ctDNA tested for ESR1m every 2–3 months, coinciding with routine imaging. Camizestrant + CDK4/6i guided by emergence of ESR1m during 1L AI + CDK4/6i in pts with HR+/HER2– ABC resulted in a statistically significant and clinically meaningful improvement in PFS. SERENA-6 is the first global Phase 3 trial to demonstrate clinical utility of using ctDNA to detect and treat emerging resistance, ahead of disease progression. These findings represent a potential new treatment strategy to optimize and improve 1L patient outcomes."

Circulating tumor DNA • Clinical • Late-breaking abstract • Metastases • P3 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • CDK4 • ER • HER-2

Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 5-year outcomes (ESMO 2025) - "Methods Pts with HR+/HER2− EBC were randomized 1:1 to RIB (400 mg/d; 3 weeks on/1 week off for 3 y) + NSAI (letrozole 2.5 mg/d or anastrozole 1 mg/d for 5 y) or NSAI alone. Men and premenopausal women received goserelin...Conclusions In this 5-year landmark analysis with mature efficacy data, RIB + NSAI reduced the risk of invasive and distant disease recurrence compared with NSAI alone, including in pts with high-risk N0 disease. A positive trend for OS in favor of RIB + NSAI continues to emerge."

Clinical • Late-breaking abstract • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: Results from the global Phase III lidERA Breast Cancer trial (SABCS 2025) - P3 | "Giredestrant, a next-generation oral selective estrogen receptor antagonist and degrader (SERD), was shown to be more potent than other SERDs (Liang 2021; Bardia 2023) and demonstrated superior antiproliferative activity vs anastrozole in the neoadj coopERA BC trial (Hurvitz 2023)... Pts with Stage I-III ER+ HER2- eBC were randomized 1:1 to giredestrant 30 mg oral daily (with an LHRH agonist in pre- and peri-menopausal women, and men) or standard-of-care ET (tamoxifen or aromatase inhibitor) for 5 years (yr)... lidERA BC is the first Phase III trial to demonstrate benefit with an oral SERD in eBC. Giredestrant tx resulted in a statistically significant and clinically meaningful IDFS improvement vs standard-of-care ET in ER+, HER2- eBC. OS trended in favor of the giredestrant arm, and DRFI was improved vs standard-of-care ET."

Clinical • P3 data • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • ER • HER-2

Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial. (PubMed, J Clin Oncol) - "Continuing adjuvant anastrozole for an additional 5 years after 5 years of initial treatment with anastrozole or tamoxifen followed by anastrozole was well tolerated and improved DFS. Although no difference in overall survival was observed as in other trials, extended anastrozole therapy could be one treatment choice in postmenopausal patients with hormone receptor-positive breast cancer."

Journal • P3 data • Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

Updated results and an exploratory analysis of ESR1m circulating tumor DNA (ctDNA) dynamics from SERENA-6, a phase 3 trial of camizestrant (CAMI) + CDK4/6 inhibitor (CDK4/6i) for emergent ESR1 mutations (ESR1m) during first-line (1L) endocrine-based therapy and ahead of disease progression in patients (pts) with HR+/HER2- advanced breast cancer (ABC) (SABCS 2025) - "Methods SERENA-6, a randomized, double-blind, phase 3 trial, enrolled pts with HR+/HER2- ABC who had received ≥6 months of 1L AI (anastrozole/letrozole) + CDK4/6i (palbociclib/ribociclib/abemaciclib). No new safety signals were observed. These results further support an early switch to CAMI + CDK4/6i during 1L therapy to delay disease progression."

Circulating tumor DNA • Clinical • Metastases • P3 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • CDK4 • ER • HER-2

Surgical outcomes in the ALTERNATE trial (Alliance A011106) -a randomized phase 3 neoadjuvant endocrine therapy (NET) trial in postmenopausal women with clinical stage II/III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) (SABCS 2025) - P3 | "In this analysis we assess the surgeons' approach in the context of NET. The ALTERNATE trial is a phase III study that randomized postmenopausal patients (pts) with clinical stage II/III ER+ HER2- BC to receive neoadjuvant anastrozole (A), fulvestrant (F), or both for 6 mos. With NET, 69.9% of pts achieved BCS, including 43.8% deemed ineligible pre-NET. Given the low rate of pCR to NET, there should not be the expectation of pCR in +LNs. Based on the procedures performed in pts with +SLNs, it appears that surgeons were applying ACOSOG Z0011 criteria for pts having BCS, but were less likely to omit ALND for +LN in pts having mastectomy."

Clinical • P3 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • ER • HER-2

OPERA-01: OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer (clinicaltrials.gov) - P3 | N=510 | Recruiting | Sponsor: Olema Pharmaceuticals, Inc. | N=370 ➔ 510

Enrollment change • Monotherapy • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Oncology • Solid Tumor • ER • HER-2

NATALEE update: Safety and treatment (tx) duration of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC) (ESMO-BC 2024) - "Methods Pts in NATALEE were randomized 1:1 to RIB (400 mg/d 3 wk on/1 wk off, 36 mo) + NSAI (letrozole or anastrozole, ≥60 mo) or NSAI alone. Men and premenopausal women also received goserelin...Table: 113MO Most common AEs (>10% in RIB + NSAI arm in the safety set) AEs, n (%) RIB + NSAI n = 2525 NSAI alone n = 2442 Neutropeniaa 1579 (62.5) 113 (4.6) Infectionsa 1253 (49.6) 883 (36.2) Arthralgia 942 (37.3) 1058 (43.3) Hepatobiliary toxicitya,b 667 (26.4) 273 (11.2) Leukopeniaa 595 (23.6) 111 (4.5) Nausea 588 (23.3) 190 (7.8) Headache 575 (22.8) 415 (17.0) Fatigue 564 (22.3) 322 (13.2) Hot flush 486 (19.2) 489 (20.0) Asthenia 428 (17.0) 291 (11.9) Alopecia 380 (15.0) 109 (4.5) Diarrhea 366 (14.5) 135 (5.5) Constipation 335 (13.3) 123 (5.0) Cough 332 (13.1) 201 (8.2) Insomnia 292 (11.6) 281 (11.5) Pyrexia 280 (11.1) 147 (6.0) Back pain 272 (10.8) 247 (10.1) Pain in extremity 261 (10.3) 219 (9.0) aGrouped term per MedDRA v. 26.0bAST, ALT, ALP, bilirubin, and GGTP..."

Clinical • Alopecia • Back Pain • Breast Cancer • CNS Disorders • Constipation • Cough • Fatigue • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hepatology • HER2 Positive Breast Cancer • Immunology • Infectious Disease • Insomnia • Leukopenia • Musculoskeletal Pain • Neutropenia • Oncology • Pain • Respiratory Diseases • Sleep Disorder • Solid Tumor • HER-2

PULMONARY TUMOR THROMBOTIC MICROANGIOPATHY: AN UNDERRECOGNIZED DRIVER OF PULMONARY HYPERTENSION IN MALIGNANCY (ACC 2026) - "Decision-Making: Group 1 PAH was presumed and IV epoprostenol was started and titrated to 12 ng/kg/min...Anastrozole was continued, but palbociclib held... Her course, imaging, and labs were most consistent with PTTM. Early recognition is vital, as prognosis is often fatal. More clinical and translational investigations are needed for this underdiagnosed complication of malignancy."

Breast Cancer • Cardiovascular • Lung Cancer • Oncology • Pulmonary Arterial Hypertension • Pulmonary Disease • Pulmonary Embolism • Respiratory Diseases • Thrombocytopenia • HP

The prognostic and predictive value of the luminal-like subtype in hormone receptor-positive breast cancer: an analysis of the DATA trial. (PubMed, ESMO Open) - P3 | "In patients with hormone receptor-positive breast cancer, the luminal B-like subtype was associated with a significantly worse prognosis when compared with the luminal A-like subtype. Extended anastrozole therapy halved the risk of DR and BCSM in patients with luminal A-like tumours, whereas no effect was seen in patients with luminal B-like tumours."

Journal • Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

A Phase II Adjuvant Trial Evaluating the Impact of Omitting Chemotherapy Based on Patient's Selection for Moderate to High-Anatomical Risk, Low-Genomic Risk, ER-positive, HER2-negative Breast Cancer with a Combination Regimen of Ribociclib and Optimized Endocrine Therapy - SELECT Trial (SABCS 2025) - P2 | "Optimized ET includes an oral aromatase inhibitor (letrozole or anastrozole) for all participants, with the addition of a GnRH agonist (goserelin) to achieve gonadal suppression in all men and premenopausal women. Recruitment is ongoing. Clinical trial information: NCT06953882."

Clinical • P2 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2

TACTIVE-N: Phase 2 study of neoadjuvant vepdegestrant, a PROteolysis TArgeting chimera (PROTAC) estrogen receptor (ER) degrader, or anastrozole in postmenopausal ER+/human epidermal growth factor receptor 2 (HER2)- localized breast cancer (BC) (ESMO 2025) - P2 | "Conclusions Neoadjuvant vepdegestrant was well tolerated and demonstrated biological and clinical activity in postmenopausal women with ER+/HER2- localized BC. Vepdegestrant led to robust ER protein degradation in tumor tissue, supporting its pharmacodynamic effect in pts with BC."

Clinical • P2 data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • ER • HER-2 • PGR

HCC 21-208: Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ (clinicaltrials.gov) - P1 | N=50 | Recruiting | Sponsor: Finn, Olivera, PhD | Trial completion date: Aug 2028 ➔ Mar 2029 | Trial primary completion date: Jan 2026 ➔ Aug 2026

Trial completion date • Trial primary completion date • Oncology • Solid Tumor • MUC1

UC-BCG-2501: NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early breast cancer treated with Ribociclib (LEE-011) innthe adjuvant setting (clinicaltrialsregister.eu) - P2/3 | N=3306 | Recruiting | Sponsor: Unicancer

Head-to-Head • New P2/3 trial • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers (clinicaltrials.gov) - P2 | N=30 | Recruiting | Sponsor: Ruth O'Regan | Trial completion date: Jan 2026 ➔ Jul 2027 | Trial primary completion date: Dec 2025 ➔ Jun 2026

Trial completion date • Trial primary completion date • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2 • PGR

Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer (clinicaltrials.gov) - P2 | N=20 | Recruiting | Sponsor: University of California, Irvine | Active, not recruiting ➔ Recruiting | Trial completion date: Dec 2028 ➔ Dec 2031 | Trial primary completion date: Dec 2025 ➔ Dec 2028

Enrollment open • Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • PGR